Proactive Investors - Run By Investors For Investors

Imugene targets cash injection for immuno-oncology clinical testing

The halt will remain in place until Thursday 23rd November 2017.
Imugene targets cash injection for immuno-oncology clinical testing
The company's shares are in pre-open

Imugene Ltd (ASX:IMU) has commenced clinical testing a therapeutic anti-cancer vaccine called HER-Vaxx (IMU131), in HER2+ gastric cancer patients.

HER-Vaxx is a next generation HER2 cancer therapy using B cell peptides, which harness the body’s ability to develop antibodies against the disease.

HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two leading antibody drugs marketed by Roche, with annual sales of US$8.2 billion.

To progress the next steps, Imugene is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.

The halt will remain in place until the opening of trade on Thursday 23rd November 2017, or earlier if an announcement is made to the market.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

cancer
February 26 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Cancer cells
February 07 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use